The Stochastic Oscillator for NBTX moved out of overbought territory on December 19, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 40 similar instances where the indicator exited the overbought zone. In of the 40 cases the stock moved lower. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NBTX entered a downward trend on December 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NBTX's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on December 13, 2024. You may want to consider a long position or call options on NBTX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on December 11, 2024. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in of 158 cases, the price rose further within the following month. The odds of a continued upward trend are .
NBTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). NBTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (3.554) is also within normal values, averaging (256.215).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NBTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SBQIX | 14.36 | 0.17 | +1.20% |
DSS AmericaFirst Large Cap Shr Buyback I | |||
MINVX | 31.01 | 0.30 | +0.98% |
Madison Investors Y | |||
PDAIX | 11.77 | 0.10 | +0.86% |
PineBridge Dynamic Asset Allc Instl | |||
JSVRX | 27.47 | 0.20 | +0.73% |
JPMorgan Small Cap Value R5 | |||
TRSSX | 24.95 | 0.12 | +0.48% |
T. Rowe Price Instl Small-Cap Stock |
A.I.dvisor tells us that NBTX and PBYI have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and PBYI's prices will move in lockstep.
Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
---|---|---|---|---|
NBTX | 100% | -5.49% | ||
PBYI - NBTX | 28% Poorly correlated | -1.08% | ||
GLMD - NBTX | 26% Poorly correlated | -0.65% | ||
PSTX - NBTX | 25% Poorly correlated | +0.43% | ||
CRMD - NBTX | 25% Poorly correlated | -3.38% | ||
GLPG - NBTX | 24% Poorly correlated | +1.48% | ||
More |